The past decade has seen considerable advances in the treatment of acute coronary syndromes (ACS), particularly in the search for improved antithrombotic therapies. Despite these successes, however, renewed efforts are needed to improve long-term outcomes after ACS by reducing recurrent ischaemic events and lowering the risk of bleeding complications.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045–1057 (2009).
Collet, J. P. et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 367, 2100–2109 (2012).
Stone, G. W. et al. Bivalirudin during primary PCI in acute myocardial infarction. N. Engl. J. Med. 358, 2218–2230 (2008).
Shahzad, A. et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(14)60924-7.
Morrow, D. A. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366, 1404–1413 (2012).
Mega, J. L. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 366, 9–19 (2012).
Mehta, S. R. et al. Early versus delayed invasive intervention in acute coronary syndromes. N. Engl. J. Med. 360, 2165–2175 (2009).
Jolly, S. S. et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 377, 1409–1420 (2011).
Menees, D. S. et al. Door-to-balloon time and mortality among patients undergoing primary PCI. N. Engl. J. Med. 369, 901–909 (2013).
Armstrong, P. W. et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N. Engl. J. Med. 368, 1379–1387 (2013).
Acknowledgements
I thank all my colleagues on both sides of the Atlantic with whom I was able to collaborate in performing important clinical trials that have improved the treatment of patients with acute coronary syndrome.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
F.V.d.W. declares that he has received research grants and fees for participating in advisory boards, data and safety monitoring boards, and speaking activities from AstraZeneca, Boehringer Ingelheim, Merck, and The Medicines Company.
PowerPoint slides
Rights and permissions
About this article
Cite this article
de Werf, F. Successes and future objectives in acute coronary syndrome. Nat Rev Cardiol 11, 624–625 (2014). https://doi.org/10.1038/nrcardio.2014.129
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2014.129
This article is cited by
-
Effectiveness of fondaparinux vs unfractionated heparin following percutaneous coronary intervention in survivors of out-of-hospital cardiac arrest due to acute myocardial infarction
European Journal of Clinical Pharmacology (2021)
